Fibrates and thiazolidinediones are commonly used for the treatment of dyslipidemia and type 2 diabetes, respectively. The aim of this study was to investigate the effects on body weight as well as on glucose and lipid homeostasis of ligands for PPARa and PPARg, Fenofibrate and Rosiglitazone, alone or in association. METHODS: Ob/ob mice were divided into four groups: control, and mice daily injected (intraperitoneally), either with 10 mg/kg Rosiglitazone, 100 mg/kg Fenofibrate or both molecules. Body weight and food intake were monitored daily. After 13 days of treatment, mice were killed, and blood samples were collected for posterior metabolite quantification. The liver and adipose tissues were dissected and weighed. RESULTS: Body weight was significantly reduced or increased by Fenofibrate and Rosiglitazone, respectively. The effect of Rosiglitazone was prevented by coadministration of Fenofibrate. This was accompanied by a normalization of the daily food efficiency. Compared to those treated with Rosiglitazone, animals treated with Fenofibrate alone or in combination presented a decreased white adipose tissue mass. Fenofibrate or Rosiglitazone alone significantly reduced the levels of plasma lipid parameters. Surprisingly, Fenofibrate also decreased blood glucose levels in ob/ob mice, despite having no effect on insulin levels. By contrast, both glucose and insulin levels were decreased by Rosiglitazone treatment. Coadministration of both drugs improved all parameters as with Rosiglitazone. Fenofibrate restored almost normal hepatocyte morphology and significantly reduced the triglyceride content of the liver. This was accompanied by an increase in fatty acid oxidation in the liver in all groups receiving Fenofibrate. CONCLUSION/INTERPRETATION: These biological effects suggest that combined therapy with a PPARa and a PPARg ligand is more effective in ameliorating, specifically, lipid homeostasis than in activating any of this receptor separately. Furthermore, Fenofibrate prevents one of the most undesirable effects of Rosiglitazone, namely increased adiposity and body weight gain.
Introduction
Thiazolidinediones (TZD) are potent insulin-sensitizer drugs used in the treatment of type 2 diabetes. 1 They are specific ligands for the peroxisome proliferator-activated receptor gamma (PPARg) transcription factor, a protein that belongs to the nuclear hormone receptor family. 2 In adults, PPARg is preferentially expressed in both adipose tissues (white and brown), although it may also be present at lower rates in the skeletal muscle, heart and liver. [3] [4] [5] PPARg directs adipocyte differentiation both in vitro and in vivo in collaboration with other transcription factors of the CCAAT/enhancer binding protein family. 6 In accordance with this role, TZD drugs (including Rosiglitazone, Pioglitazone and Troglitazone, of which the last has been withdrawn because of liver toxicity), despite normalizing glycemia and insulinemia, promote body weight gain both in animals and humans [7] [8] [9] [10] [11] [12] and adipogenesis in vitro. [13] [14] [15] This is one of the main side effects of TZD treatment, and current investigation focuses on correcting this undesirable consequence. PPARa was the first member of the PPAR family to be described. 16 It is mainly expressed in tissues with high metabolic activity such as the liver, heart, kidney, muscle and brown adipose tissue, 17, 18 as well as in vascular endothelial cells, macrophages and monocytes. 19, 20 Fibrates are synthetic ligands for PPARa and are used for the treatment of dyslipidemia, especially hypertriglyceridemia and hypercholesterolemia. 21 The former has been proposed to contribute to the development of insulin resistance and type 2 diabetes in humans. Thus, fibrates lower plasma triglycerides and cholesterol in these patients 21, 22 as well as in murine models of insulin resistance and type 2 diabetes, probably by ameliorating liver function and lipid catabolism in this organ. 23 In contrast to TZD, fibrates have been reported to induce no change in body weight or even to decrease it in some models of obesity in rodents 24, 25 and in patients with metabolic X syndrome. 26 In the past few years, dual PPARa and PPARg agonists have been developed and their utility as antidiabetic drugs has been suggested. [27] [28] [29] [30] [31] Nevertheless, only few reports have explored the effects of cotreatment with PPARa and PPARg agonists, 7, 30 particularly when focusing on body weight regulation.
The aim of the present study was to investigate the effects on glucose and lipid homeostasis as well as on body weight of two well-known specific ligands for PPARa and PPARg, Fenofibrate and Rosiglitazone, alone or in association, the hypothesis being that they would exert additional beneficial effects for the treatment of type 2 diabetes compared to separately activating both receptors. 
Methods

Chemicals
Metabolite measurements
Blood glucose levels were measured using Glucotrend s and Accu-Check s active systems (Roche; Mannheim, Germany). Serum NEFA was determined using an acyl-CoA oxidasebased colorimetric kit (NEFA-C, Wako Pure Chemicals Industries; Neuss, Germany). Serum and liver triglycerides were measured using enzymatic colorimetric methods (Triglycerides Enzymatic PAP150, BioMérieux; Marcy-l'Etoile, France). Serum insulin levels were determined by an immunoassay enzymatic system (Mercodia Ultrasensitive Mouse Insulin ELISA, Mercodia; Uppsala, Sweden). Serum cholesterol levels were measured using a colorimetric kit from Sigma-Aldrich (Saint Quentin Fallavier, France).
Histological analysis
Liver specimens were fixed on 100% ethanol for histological analysis and embedded in paraffin. Sections were cut at a thickness of 5 mm and stained with hematoxylin/eosin.
Liver triglyceride extraction and determination Liver triglyceride extraction was performed as previously described. 32 Frozen liver samples (200-600 mg) were minced in chloroform and methanol (2:1 ratio) and incubated overnight at 41C. After filtration to remove tissue debris, 0.9% NaCl was added, and samples were centrifuged at 1500 r.p.m. for 10 min. Lipids in the organic phase were transferred to a new tube, air-dried and dissolved again with X-Triton, methanol and tert-butilic alcohol (1:1:3 ratio).
Fatty acid oxidation in liver
Palmitate oxidation rates were measured in liver homogenates as previously described. 33 Small fragments of liver were homogenized in Set buffer (250 mM sucrose, 2 mM EDTA, 10 mM Tris, pH 7.4) and 75 ml were incubated in 300 ml of oxidation buffer (27 mM KCl, 10 mM KH 2 PO 4 , 5 mM MgCl 2 , 1 mM EDTA, 25 mM sucrose, 75 mM Tris, 5 mM ATP, 1 mM NAD þ , 25 mM cytochrome c, 0.1 mM coenzyme A, 0.5 mM L-carnitine, 0.5 mM L-malate, pH7.4) in glass vials. After a 5-min preincubation at 371C in a shaking water bath, the reaction was started by adding 100 ml of 600 mM CO 2 produced was trapped in 300 ml ethanolamine/ethylene glycol (1:2 v/v) and measured using a liquid scintillation counter. After 90 min at 41C, the acid incubation mixture was centrifuged (5 min at 10 000 g) and 500 ml of supernatant containing the 14 C-perchloric acid acid-soluble products was assayed for radioactivity by liquid scintillation. Palmitate oxidation rates were calculated from the sum of 14 CO 2 and 14 C-percholic acid-soluble products and expressed in nmol of palmitate per min per g tissue weight, or pmol of palmitate per min per mg of protein.
Whole-body fat composition
A PIXIMUS densitometer (LUNAR Corporation, Madison, WI, USA) was used for measurement of whole-body fat. Calibration was performed with a defined standard (phantom). After decapitation, mice were placed on a specimen tray and put in a PIXIMUS imaging area for analysis. The PIXIMUS software automatically calculated the whole-body fat and lean mass content.
Statistical analysis
Data are expressed as means7s.e.m. Prism Software (GraphPad software, San Diego, CA, USA) was used for all statistical analysis. A one-way analysis of variance followed by Tukey's multiple comparison test was used to assess the statistical difference between groups. When appropriate, the unpaired t-test was performed.
Results
Fenofibrate prevents Rosiglitazone-induced body weight gain in ob/ob mice Fenofibrate significantly reduced body weight in ob/ob mice compared to control mice whereas Rosiglitazone induced a significant increase (Figure 1) . Thus, at the end of the treatment, the body weight change was 2.7470.42 g for control-vehicle mice, À0.8470.92 g for Fenofibrate-treated mice (Po0.001 vs control and Rosiglitazone-treated animals) and 6.9670.94 g for Rosiglitazone-treated mice (Po0.001 vs control). The increase in body weight associated with Rosiglitazone treatment was prevented by the coadministration of Fenofibrate. Thus, at day 13, these mice had a body weight not significantly different from that of controls or Fenofibrate-treated mice (0.6771.02 g, Po0.001 vs Rosiglitazone group).
Fenofibrate prevents hyperphagia in Rosiglitazonetreated mice Changes in body weight were associated with differences in food consumption. Rosiglitazone-treated mice were hyperphagic compared to controls (5.6070.15 and 5.0870.09 g/ day, respectively, Po0.01) (Figure 2a) , whereas Fenofibratetreated animals, or mice treated with both molecules, had a (Figure 2b ).
Blood chemistry in ob/ob treated mice As expected, Fenofibrate alone significantly reduced serum triglyceride (42% reduction, Po0.001. vs control), nonesterified fatty acid (5% reduction, Po0.001 vs control) and total cholesterol levels (50% reduction, Po0.001 vs control). Surprisingly, it also decreased blood glucose levels in ob/ob mice (34% reduction, Po0.01 vs control), despite having no effect on insulin levels (Table 1) . Rosiglitazone alone had similar effects to Fenofibrate on lipid parameters, being even more efficient than Fenofibrate in reducing cholesterol levels (Po0.001). Furthermore, glucose and insulin levels were also decreased by Rosiglitazone treatment. The coadministration of both drugs improved all parameters as with Rosiglitazone administration.
Fenofibrate decreases liver triglyceride content, stimulates fatty acid oxidation and normalizes hepatocyte morphology Despite no significant changes in liver weight, Fenofibrate treatment significantly reduced the triglyceride content of the liver both when used alone (48.4%. reduction) or in combination with Rosiglitazone (62% reduction) ( Table 2) . Palmitic acid oxidation was increased by Fenofibrate treatment, either alone or in combination with Rosiglitazone. Notably, the association of both molecules further increased lipid oxidation compared to Rosiglitazone treatment alone (118% increase per g of the liver and 113% increase per mg of the protein vs the Rosiglitazone group, Po0.001 and Po0.01, respectively). Histological sections of the liver reflected these biochemical changes. Thus, Fenofibratealone , and Rosiglitazone plus Fenofibrate treatments restored hepatocyte morphology, with a great reduction in the size and number of lipid droplets compared to hepatocytes from control and Rosiglitazone-treated mice ( Figure 3 ).
Fenofibrate effects on fat mass in ob/ob mice Rosiglitazone treatment significantly increased inguinal and epidydimal white adipose tissue (WAT) weights compared to control mice (15 and 24% increase, respectively), resulting in a total WAT weight increase of 19% (sum of inguinal and epidydimal depots) ( Table 3 ). Compared to those treated with Rosiglitazone, animals treated with Fenofibrate alone or in combination had less white adipose tissue (20 and 21% reduction, respectively, for inguinal depot, and 19 and 10% for epidydimal pad) ( Table 3) . Total WAT of Fenofibratetreated mice (alone and in combination with Rosiglitazone) was also significantly reduced compared to Rosiglitazonetreated mice (Po0.001). X-ray densitometer analysis (PIX-IMUS) showed that the percentage of body fat mass was diminished in animals treated with Fenofibrate alone or in combination with Rosiglitazone (6% reduction vs Rosiglitazone for both situations). It is interesting to note that absolute fat mass was increased in Rosiglitazone-treated Values are mean7s.e. (n ¼ 6-7). One-way analysis of variance denoted significant differences between groups for glucose (Po0.0017), insulin (Po0.0000), triglyceride (Po0.001), NEFA (Po0.0000) and total cholesterol levels (Po0.0000). *Significantly different from control mice Po0.01; wPo0.001. zSignificantly different from Rosiglitazone-treated mice Po0.001. y Significantly different from Fenofibrate-treated mice Po0.001. GLC, glucose; INS, insulin; TG, triglycerides; NEFA, nonesterified fatty acids; CHOL, total cholesterol. Fibrate prevents body weight gain in ob/ob mice MC Carmona et al
Discussion
In this study, we describe the benefits of combining PPARg and PPARa ligands for the treatment of type 2 diabetes. As reported repeatedly, Rosiglitazone improves blood levels of glucose, insulin, triglycerides, NEFA and cholesterol. 7, 27, 29, 31, 34, 35 On the other hand, Fenofibrate alone was, indeed, able to reduce serum lipid levels (TG, NEFA and cholesterol). 7, 25, 36 Surprisingly, it was also able to reduce significantly blood glucose concentration despite no effect on plasma insulin. Such an effect on blood glucose has already been reported in db/db mice, 7 although the effect was found to be less pronounced in these later. Combined activation of the two receptors markedly prevents glucose and lipid dysregulations in the ob/ob mice as Rosiglitazone does. Recently, some investigations have reported the effects of dual PPARa/g agonist in animal models of dyslipidemia and type 2 diabetes. [27] [28] [29] [30] [31] Our data are in good agreement with these reports, although in most of them, either no comparison was made with a specific PPARg agonist, or the dual agonist did not show a beneficial effect. The most striking result of the present study concerns the effect of Fenofibrate on body fat mass and body weight. Indeed, Fenofibrate alone decreased body weight in ob/ob mice. This effect is highly significant and persists over time. Such a decreased body weight and fat mass have already been reported in models of genetic or diet-induced obesity in rodents treated with Fenofibrate or PPARa agonist alone. 24, 25, 31, [36] [37] [38] [39] One of the side effects of PPARg ligands is their tendency to increase body weight, which is a risk factor for type 2 diabetes. Rosiglitazone-treated animals had increased body and WAT weights. Furthermore, absolute lean mass was increased in this group in line with the fat mass, which explains the no-change observed in the percentage of body fat. Fenofibrate totally prevents the higher body weight gain induced by Rosiglitazone and reduces white fat mass. This clear-cut effect contrasts with those of the recent dual PPARa/g ligands developed, which are rather controversial. Some have been reported to increase body weight like Rosiglitazone does, 27, 28, 30 whereas others have no effect. 29, 39 However, it should be noted that in the two last papers, Rosiglitazone was not reported to increase body weight as well. So this is the first report demonstrating that a treatment with a PPARa ligand is able to prevent body weight gain induced by a PPARg agonist. The changes in body weight might be related to the effects of the different treatment on food intake. Thus, Rosiglitazone and Fenofibrate alone induced hyperphagia and hypophagia, respectively. The effect of Fenofibrate appears to be predominant since cotreatment resulted in a decreased food intake compared to controls. This is probably not due to variations in leptin levels, since our model is the ob/ob mouse that lacks this hormone, 40 but rather to changes in metabolic parameters, which in turn would regulate body weight and adipose tissue mass, as already suggested by Guerre-Millo et al.
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Long-term PPARa activation is usually associated with hepatomegaly. 24, 31, 41 In the present work, no changes in liver weight were observed whatever the treatment used. However, Fenofibrate alone or in combination with Rosiglitazone, significantly reduced liver TG content, probably by ameliorating lipid metabolism in this organ (increased lipid oxidation), compared to Rosiglitazone alone or to control animals. This may contribute to the reduction in serum lipid metabolites observed in the Fenofibrate-treated animals (in combination with Rosiglitazone or not). These results suggest that cotreatment with both molecules zmay ameliorate fatty liver without increasing liver mass, and thus contributes to the therapeutic potential of PPARa/g ligands.
To summarize, the present study demonstrates that combined therapy with a PPARa and a PPARg ligand is more effective in ameliorating lipid homeostasis than activating any of these receptors separately, contributing to the amelioration of the diabetic state. Furthermore, Fenofibrate prevents one of the most undesirable effects of Rosiglitazone, namely increased adiposity and body weight gain. This sustains the current development of the PPARa/g compound as a valuable approach for the treatment of type 2 diabetes. Po0.01; f Po0.05. iBAT, interescapular brown adipose tissue; iWAT, inguinal white adipose tissue; eWAT, epididimal white adipose tissue; tWAT, total white adipose tissue; % Fat, percentage of fat versus the whole body calculated using the PIXIMUS densitometer; FAT MASS, absolute fat mass calculated using the PIXIMUS densitometer; LEAN MASS, absolute lean mass calculated using the PIXIMUS densitometer.
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